Amsterdam Molecular Therapeutics Receives Further Opinion on Glybera Marketing Authorisation Application

Amsterdam Molecular Therapeutics (AMT) Holding N.V. (in liquidatie) (Euronext: AMT), a leader in the field of human gene therapy, has received notice that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has maintained its earlier opinion that Glybera (alipogene tiparvovec) is not approvable at this time.

The decision was reached contrary to the majority of votes cast by the CHMP itself, which voted 16 – 15 in favor of approving Glybera under exceptional circumstances. It is also contrary to the earlier positive advice of the Committee for Advanced Therapies (CAT), a committee specifically implemented to provide expert guidance to the CHMP on advanced therapeutics such as geneand cell therapies. In addition, the Scientific Advisory Group (SAG), an expert panel specifically selected to evaluate clinical results and the science of the product, also recommended that Glybera should be approved under exceptional circumstances.

The SAG and the CAT, after extensive review and analysis of data (including interviews with the investigator, the leading clinicians and patients), concluded that Glybera demonstrated meaningful evidence of clinical efficacy, without any major safety concerns. However, members of the CHMP are not bound to follow the advice of the experts from CAT and SAG.

For a drug to receive a positive opinion the rules require an absolute majority from all CHMP members, including those who do not participate in the meeting and the vote. The CHMP is composed of 32 voting members, and at least 17 positive votes are required. Accordingly, this vote of 16 – 15 in favor of Glybera represents a negative opinion.  Members absent at the time of the vote cannot vote by proxy or retrospectively.

The final step in the procedure is now with the European Commission to confirm, or not, the CHMP’s opinion.

“We find it hard to explain to LPLD patients who suffer from extremely painful, recurring, potentially lethal pancreatitis attacks, and for whom Glybera is the only therapeutic option, that they will now be deprived of a treatment when a great majority of the scientific experts involved recommended Glybera for approval and the majority of the CHMP voting members shared the experts’ view”, said Jörn Aldag, liquidator of AMT (and CEO of uniQure B.V., its successor company). “While we are deeply disappointed with the current outcome on Glybera, we are encouraged by the validation provided by the majority verdict of the CHMP’s voting members, the Scientific Advisory Group and the Committee for Advanced Therapies regarding our gene therapy platform, which indicates that neither safety nor GMP quality are an issue.”

AMT has recently transferred its gene therapy assets to a new company, uniQure B.V., which will continue its focus on strategic advancement of the promising projects in its development pipeline.